Physician profile
Steven E Hodes
NPI 1578561759
$32,487.56
in general payments reported to CMS, 2019-2025
42 companies · $4,545 in 2025
The $4,545 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,767 · 2020: $843 · 2021: $1,214 · 2022: $1,560 · 2023: $1,838 · 2024: $15K · 2025: $4,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $7,317 · Education: $27.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,760.00 |
| Food and Beverage | $7,316.55 |
| Education | $27.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $14,740.46 | 2024-2025 | Voquezna |
| Allergan, INC. | $5,596.02 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,740.78 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $2,495.58 | 2019-2025 | |
| Janssen Biotech, INC. | $1,181.76 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $730.15 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $701.31 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $516.36 | 2019-2024 | Linzess |
| Pfizer INC. | $434.78 | 2019-2025 | |
| Ardelyx, INC. | $327.41 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $326.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $240.50 | 2023-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $237.99 | 2019-2024 | Dificid, Zerbaxa |
| Lilly USA, LLC | $236.21 | 2023-2025 | Omvoh |
| Redhill Biopharma INC. | $216.99 | 2020-2024 | Talicia, Aemcolo, Movantik |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.